Country: Malta
Language: English
Source: Medicines Authority
GEMCITABINE
Ebewe Pharma GmbH Nfg. KG Mondseestrasse 11, 4866 Unterach, Austria
L01BC05
GEMCITABINE
POWDER FOR SOLUTION FOR INFUSION
GEMCITABINE
POM
ANTINEOPLASTIC AGENTS
Withdrawn
2011-03-18
Page 1 of 7 PACKAGE LEAFLET: INFORMATION FOR THE USER GEMCITABINE 200 MG POWDER FOR SOLUTION FOR INFUSION GEMCITABINE 1000 MG POWDER FOR SOLUTION FOR INFUSION GEMCITABINE READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START RECEIVING THIS MEDICINE. - Keep this leaflet. You may need to read it again. - If you have further questions, please ask your doctor, nurse or pharmacist. - This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. - If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, nurse or pharmacist. IN THIS LEAFLET: 1. What Gemcitabine powder for solution for infusion is and what it is used for 2. Before you are given Gemcitabine powder for solution for infusion 3. How Gemcitabine powder for solution for infusion is given 4. Possible side effects 5. How to store Gemcitabine powder for solution for infusion 6. Further information 1. WHAT GEMCITABINE POWDER FOR SOLUTION FOR INFUSION IS AND WHAT IT IS USED FOR Gemcitabine powder for solution for infusion belongs to a group of medicines called “cytotoxics”. These medicines kill dividing cells, including cancer cells. Gemcitabine powder for solution for infusion may be given alone or in combination with other anti-cancer medicines, depending on the type of cancer. Gemcitabine powder for solution for infusion is used in the treatment of the following types of cancer: • non-small cell lung cancer (NSCLC), alone or t Read the complete document
Page 1 of 17 SUMMARY OF THE PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Gemcitabine 200 mg powder for solution for infusion Gemcitabine 1000 mg powder for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One vial contains gemcitabine hydrochloride equivalent to 200 mg gemcitabine. One vial contains gemcitabine hydrochloride equivalent to 1000 mg gemcitabine. After reconstitution, the solution contains 38 mg/ml of gemcitabine. Excipients Each 200 mg vial contains 3.9 mg (<1 mmol) sodium. Each 1000 mg vial contains 19.6 mg (<1 mmol) sodium. For a full list of excipients see section 6.1. 3. PHARMACEUTICAL FORM Powder for solution for infusion. White to off-white cake or powder. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Gemcitabine is indicated for the treatment of locally advanced or metastatic bladder cancer in combination with cisplatin. Gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. Gemcitabine, in combination with cisplatin is indicated as first line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). Gemcitabine monotherapy can be considered in elderly patients or those with performance status 2. Gemcitabine is indicated for the treatment of patients with locally advanced or metastatic epithelial ovarian carcinoma, in combination with carboplatin, in patients with relapsed disease following a recurrence-free interval of at least 6 months after platinum-based, first- line therapy. Gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or Read the complete document